BioSyntech reaches significant BST-CarGel(R) clinical milestone



    LAVAL, QC, June 14 /CNW/ - BioSyntech Inc. (TSX: BSY) announced today
that it has completed the enrolment of a 20 patient subset of its ongoing
Canadian-European BST-CarGel(R) pivotal trial. The data collected from these
patients will be submitted to the U.S. Food and Drug Administration as a pilot
study in support of an Investigational Device Exemption (IDE) for a US pivotal
trial.
    "We have reached an important milestone for the Company," said Claude
Leduc, President and CEO of BioSyntech, "because this pilot study should
permit us to advance directly to a US pivotal trial, and pave the way for
commercialization."
    BioSyntech's current Canadian-European multicenter clinical trial for
BST-CarGel(R) is targeting 80 patients. The objective of the trial is to
assess BST-CarGel(R) safety as well as its ability to repair focal articular
cartilage damage in the knee, and is intended to support market approvals in
Canada and Europe.

    About BST-CarGel(R)

    BST-CarGel(R) is a promising new therapeutic approach for repair of
localized cartilage lesions. Applied during minimally-invasive surgery, it
acts in situ as a 3-dimensional scaffold and may guide the repair of the
damaged cartilage.

    About BioSyntech

    BioSyntech is a biotechnology company specializing in the discovery,
development and manufacturing of innovative cost-effective and
physician-friendly therapeutic thermogels for regenerative medicine and
therapeutic delivery. BioSyntech's Quality Management System is registered to
ISO 9001:2000 standards. For additional information, visit www.biosyntech.com.

    This press release contains forward-looking statements, including,
without limitation, statements containing the words "believe", "may", "plan",
"will", "estimate", "continue", "anticipate", "intend", "expect" and other
similar expressions which constitute "forward-looking information" within the
meaning of applicable Canadian securities laws, which reflect the Company's
current expectation and assumptions, and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
anticipated. These forward-looking statements involve risks and uncertainties
including, but not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of corporate
alliances, the impact of competitive products and pricing, new product
development, uncertainties related to the regulatory approval process and
other risks detailed from time-to-time in the Company's ongoing filings with
the Canadian securities regulatory authorities which filings can be found at
www.sedar.com. Given these risks and uncertainties, readers are cautioned not
to place undue reliance on such forward-looking statements. The Company
undertakes no obligation to publicly update or revise any forward-looking
statements either as a result of new information, future events or otherwise.

    %SEDAR: 00020217E




For further information:

For further information: BioSyntech, Inc., Yvonne Kramer Ph.D., Sen.
Director Corporate & Business Development, (450) 686-2437, ext. 315,
Yvonne.kramer@biosyntech.com; Investor relations, The Equicom Group Inc., Eric
Bouchard, (514) 844-7997, ebouchard@equicomgroup.com

Organization Profile

BIOSYNTECH, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890